Price T Rowe Associates Inc Pliant Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 4,602,323 shares of PLRX stock, worth $52.1 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,602,323
Previous 3,959,088
16.25%
Holding current value
$52.1 Million
Previous $59 Million
16.13%
% of portfolio
0.01%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding PLRX
# of Institutions
158Shares Held
63.8MCall Options Held
481KPut Options Held
105K-
Deep Track Capital, LP Greenwich, CT5.97MShares$67.5 Million2.11% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$56.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.44MShares$38.9 Million0.0% of portfolio
-
First Light Asset Management, LLC Edina, MN3.4MShares$38.5 Million3.33% of portfolio
-
Redmile Group, LLC San Francisco, CA3.21MShares$36.3 Million2.25% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $551M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...